Hansa Biopharma AB (HNSAN) Financial Statements
Hansa Biopharma AB Financial Overview
Hansa Biopharma AB's market cap is currently $7.66B. The company's EPS TTM is $-7.86; its P/E ratio is -5.00; Hansa Biopharma AB is estimated to report earnings on November 11, 2026, and the estimated EPS forecast is $-2.71. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 222.26M | $ 171.32M | $ 134.09M | $ 154.53M | $ 33.88M |
| Gross Profit | $ 138.71M | $ 87.76M | $ 70.95M | $ 116.05M | $ 18.45M |
| Operating Income | $ -520.71M | $ -637.88M | $ -788.50M | $ -576.12M | $ -539.58M |
| EBITDA | $ -483.82M | $ -642.07M | $ -705.50M | $ -554.26M | $ -538.83M |
| Net Income | $ -534.11M | $ -807.24M | $ -831.72M | $ -611.13M | $ -548.28M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 701.08M | $ 405.28M | $ 732.06M | $ 1.50B | $ 888.96M |
| Total Assets | $ 1.17B | $ 800.64M | $ 1.02B | $ 1.69B | $ 1.01B |
| Total Debt | $ 933.82M | $ 1.08B | $ 866.77M | $ 791.09M | $ 35.38M |
| Net Debt | $ 232.73M | $ 673.73M | $ 134.71M | $ -705.09M | $ -615.96M |
| Total Liabilities | $ 1.25B | $ 1.39B | $ 1.19B | $ 1.08B | $ 255.24M |
| Stockholders' Equity | $ -88.99M | $ -589.83M | $ -167.88M | $ 602.91M | $ 757.57M |
| Cash Flow | |||||
| Free Cash Flow | $ -549.17M | $ -675.00M | $ -755.94M | $ -506.06M | $ -483.57M |
| Operating Cash Flow | $ -549.17M | $ -674.88M | $ -755.65M | $ -502.73M | $ -481.17M |
| Investing Cash Flow | $ 0.00 | $ -116.00K | $ -284.00K | $ 229.31M | $ -2.40M |
| Financing Cash Flow | $ 847.96M | $ 346.81M | $ -7.54M | $ 1.12B | $ -4.86M |
Currency in SEK
